Aristopin O/Sol effectively slows the progression of childhood myopia, as evidenced by clinical studies and endorsements from leading ophthalmology organizations. With its low-dose 0.01% Atropine formulation, Aristopin minimizes common side effects, making it suitable for long-term use in children.
The duration of treatment with Aristopin (Atropine 0.01% ) O/Sol, can vary depending on the individual child's response and the progression of their myopia. Generally, the treatment is recommended for a minimum of two years. However, it can be continued up to the age of 12 or until the child's eye growth stabilizes. Regular check-ups with an ophthalmologist are essential to monitor the effectiveness of the treatment and to make any necessary adjustments.
FR
DE